MENU
Go to the list of all blogs
Anna G's Avatar
published in Blogs
Jun 21, 2023

81% Chance of Trend Reversal: Crinetics Pharmaceuticals (CRNX) Price Analysis and Market Overview

Crinetics Pharmaceuticals (CRNX) has recently shown an interesting price movement, as it exceeded its 50-day Moving Average on June 16, 2023. This upward price move could potentially indicate a change in the trend, possibly leading to a sell signal for investors. Analyzing historical data, A.I.dvisor found 54 similar cases, with 44 of them resulting in successful outcomes. Based on this data, the odds of success in a potential trend reversal are estimated to be around 81%. 

Are you ready to embrace the future of trading? Tickeron's AI robots empower investors to make smarter decisions.

Another significant indicator to consider is CRNX's RSI (Relative Strength Index) Indicator. On May 11, 2023, the 10-day RSI Oscillator for CRNX moved out of the overbought zone. This shift could suggest a potential shift from an upward trend to a downward trend. Traders and investors might want to carefully assess their positions, considering options such as selling the stock or buying put options. Tickeron's A.I.dvisor reviewed 27 instances where the RSI Indicator moved out of the overbought zone, and in 25 of those cases, the stock moved lower in the following days. This historical analysis provides a compelling 90% probability of a downward price move.

Considering the overall market dynamics in the biotechnology industry, it's important to understand CRNX's position in terms of market capitalization. The average market capitalization in the biotechnology industry stands at 2.17B, with a range spanning from 402 to 363.53B. NONOF holds the highest valuation in this group at 363.53B, while the lowest-valued company is PNEXF at 402.

Examining price movements in the biotechnology industry, the average weekly price growth is 1%, while the average monthly price growth is 12%. Over the span of a quarter, the average price growth reaches 39%. Notable stocks in this industry include GLSH, which experienced the highest price growth at 240%, and NBCO, which suffered the biggest fall at -80%.

Furthermore, considering volume trends in the biotechnology industry, the average weekly volume growth is 243%, indicating significant market activity. On a monthly basis, the average volume growth is 203%, while over a quarter, it reaches 11%. These volume dynamics demonstrate the active nature of the industry, with traders and investors closely monitoring stock movements.

Lastly, assessing the fundamental analysis ratings of CRNX, we find valuable insights. The valuation rating stands at 50, indicating a relatively balanced valuation. The P/E Growth Rating is at 87, reflecting positive growth potential. The Price Growth Rating is at 57, suggesting moderate price growth expectations. Additionally, the SMR Rating is at 93, indicating strong sales, margin, and return characteristics. The Profit Risk Rating stands at 94, highlighting potential risks in the company's profitability. Lastly, the Seasonality Score is at 6, indicating a neutral seasonality trend.

As always, it's important to conduct thorough research, consult with financial advisors, and carefully consider your investment goals before making any decisions based on market analysis. Understanding the various indicators and ratings can provide valuable insights, but market conditions can change rapidly. Stay informed and make investment decisions that align with your risk tolerance and long-term objectives.

Related Ticker: CRNX

CRNX's RSI Oscillator ascends from oversold territory

The RSI Indicator for CRNX moved out of oversold territory on April 09, 2025. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 20 similar instances when the indicator left oversold territory. In of the 20 cases the stock moved higher. This puts the odds of a move higher at .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on April 17, 2025. You may want to consider a long position or call options on CRNX as a result. In of 101 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for CRNX just turned positive on April 15, 2025. Looking at past instances where CRNX's MACD turned positive, the stock continued to rise in of 53 cases over the following month. The odds of a continued upward trend are .

CRNX moved above its 50-day moving average on April 24, 2025 date and that indicates a change from a downward trend to an upward trend.

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where CRNX advanced for three days, in of 280 cases, the price rose further within the following month. The odds of a continued upward trend are .

CRNX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 5 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where CRNX declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

The Aroon Indicator for CRNX entered a downward trend on April 07, 2025. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock slightly better than average.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. CRNX’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.274) is normal, around the industry mean (14.237). P/E Ratio (0.000) is within average values for comparable stocks, (63.881). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.827). Dividend Yield (0.000) settles around the average of (0.024) among similar stocks. CRNX's P/S Ratio (2500.000) is slightly higher than the industry average of (255.011).

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

Notable companies

The most notable companies in this group are Regeneron Pharmaceuticals (NASDAQ:REGN), Incyte Corp (NASDAQ:INCY), Moderna (NASDAQ:MRNA), Exelixis (NASDAQ:EXEL), Sarepta Therapeutics (NASDAQ:SRPT), Arrowhead Pharmaceuticals (NASDAQ:ARWR), BioCryst Pharmaceuticals (NASDAQ:BCRX), Adaptive Biotechnologies Corp (NASDAQ:ADPT), Novavax (NASDAQ:NVAX), Nektar Therapeutics (NASDAQ:NKTR).

Industry description

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

Market Cap

The average market capitalization across the Biotechnology Industry is 2.16B. The market cap for tickers in the group ranges from 151 to 275.91B. NONOF holds the highest valuation in this group at 275.91B. The lowest valued company is MYMX at 151.

High and low price notable news

The average weekly price growth across all stocks in the Biotechnology Industry was 7%. For the same Industry, the average monthly price growth was -4%, and the average quarterly price growth was -12%. RLMD experienced the highest price growth at 154%, while VINC experienced the biggest fall at -75%.

Volume

The average weekly volume growth across all stocks in the Biotechnology Industry was 14%. For the same stocks of the Industry, the average monthly volume growth was 12% and the average quarterly volume growth was 11%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 50
P/E Growth Rating: 84
Price Growth Rating: 70
SMR Rating: 91
Profit Risk Rating: 94
Seasonality Score: -1 (-100 ... +100)
View a ticker or compare two or three
CRNX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a developer of therapeutics for endocrine-related diseases

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Pharmaceuticals Major
Address
6055 Lusk Boulevard
Phone
+1 858 450-6464
Employees
290
Web
https://www.crinetics.com
Ad is loading...
Paper wallets are extremely useful tools – beyond being one of the most popular and secure cold storage methods, they make it simple to transfer coins between owners.You can access the funds on your paper wallet by “sweeping” (or importing) them to either a live wallet (like Trezor or Exodus) or an exchange service (like Coinbase). Most services allow you to import them directly from your wallet’s private key, but there are two key exceptions.
"🚀 PHAXIAM Therapeutics SA Skyrockets +18.82%! Dive into this biotech penny stock's stellar week and the industry's broader movements. 📈🔬
Explore annualized returns of +110% for Day Traders and +50% for Swing Traders using Price Action Trading Strategies (TA&FA) on popular managed healthcare stocks like $BIOS $CI $CNC $ELV $HUM $MOH $UNH. Stay updated on the 1-week change of +3% in this dynamic market.
The ethanol industry encompasses a diverse range of business activities, primarily focusing on the production of ethanol and sugar. Beyond these core products, companies within this theme also engage in the development of related assets, such as fuel storage tanks.
Cisco Systems set to soar! 🚀 A.I. predicts +4% growth in the coming month. Is CSCO the next big move in your portfolio? 📈💰
#trading
The Office Equipment/Supplies sector has emerged as a standout performer in recent times, posting an impressive 6.13% increase in its performance over the past week. This surge in performance is supported by a group of tickers, including $ACTG, $SCS, $HNI, $EBF, and $ACCO, which have collectively displayed a positive outlook. In this article, we will delve into the theme of this sector and analyze the group of tickers within it that are driving this positive momentum.
"IBM Skyrockets: +15.54% Quarterly Jump! Dive into the data behind this tech titan's remarkable rally. 📈🚀"
#investment#trading
The pharmaceutical sector is known for its dynamic nature, with companies often experiencing rapid shifts in performance and sentiment. In the past week, pharmaceutical companies, as represented by a group of tickers including RPRX, CALT, INZY, and HRMY, have seen a noteworthy increase in performance, surging by +3.13%. In this article, we will delve into the details of this trend, explore key indicators, and assess the outlook for these companies.
The term 'challenging disorders' envelops a vast expanse of the healthcare sector, extending from medical devices, facilities to biotechs, and pharmaceutical firms.
The ocean transportation sector has been making waves recently, experiencing a significant performance boost of +3.74% over the past week. In this article, we'll delve into the theme and explore the key tickers within this sector, shedding light on their market capitalization, recent price movements, volume trends, and fundamental analysis ratings.
The medical companies segment has experienced a notable increase in performance, recording a weekly gain of +3.53%. This sector encompasses companies involved in the production and supply of pharmaceuticals and essential medical products, catering to a broad spectrum of healthcare needs. Their product offerings include surgical apparel, gloves, hospital furniture, fluid management solutions, and specialized equipment for cosmetic and surgical procedures.
Tickeron launches AI-powered Stock Picker robots to assist hedge fund managers with sector rotation, growth-focused small-cap stocks, and strategic risk management. Using proprietary FLMs, Stock Pickers offer quant-driven signals and adaptive strategies for long-term growth and investment
Tickeron unveils an intuitive AI trading bot interface, offering tailored strategies for day, swing, and trend traders. From beginners to pros, discover tools designed to optimize trading precision, adapt to market volatility, and provide hedge fund-level insights for smarter investments.
#latest#popular#trading
Learn the 27 essential intraday trading rules that every manual trader should master—and discover how Tickeron’s AI platform applies them automatically for consistent, emotion-free execution and smarter, real-time decision-making.
#investment#trading
A $2 trillion sell-off has investors asking: is 2025 the next dot-com crash or a replay of the 2008 recession? This deep dive compares both scenarios, outlines warning signs, and reveals how AI-powered trading strategies can help navigate rising volatility.
#trading#investment
New to trading? Discover 21 powerful lessons every beginner must learn—and see how Tickeron’s AI Double Agent strategies apply them in real time. From mastering risk to managing emotions, this guide helps you trade smarter, safer, and more confidently.
#investment#trading
From the railroads of the 1920s to the AI giants of 2025, market history shows that extreme concentration often precedes massive bubbles and crashes. This article explores five key turning points and how Tickeron’s AI helps traders navigate today’s bubble-prone landscape.
#investment#trading
U.S. tariff tensions rocked markets this week, sending tech stocks into retreat and safe-haven assets like gold and the yen soaring. As investors brace for major earnings and global policy shifts, volatility remains high across equities, currencies, and commodities.
#investment#trading
Tesla’s Q1 2025 earnings could surprise investors as the EV giant looks to rebound from last quarter’s miss. With lowered expectations and increased volatility, Tickeron’s AI-powered strategy helps traders navigate both upside potential and downside risk.
#investment#trading
Gold is on a historic run—up 29% YTD with record-breaking inflows and growing macro tailwinds. Discover why smart investors are eyeing gold, silver, and miners for opportunity, and how AI trading tools are unlocking new ways to profit from the 2025 gold rush.
#investment#trading